Targeted Therapies in Older Patients with Metastatic Colorectal Cancer

摘要: During the last years, targeted therapies have been incorporated to treatment of patients with metastatic colorectal cancer. Whereas main pivotal or registry studies these drugs did not systematically exclude elderly people, they formed a minority cohorts. Data from nonselected by age and age-selected suggest that alone should be an exclusion criterion for receiving bevacizumab plus CT in mCRC. Fit derive similar benefit terms RR, PFS, OS use CT. All are consistent establishing increased incidence ATEs respect younger ones, therefore, those recent episode myocardial infarction, stroke, any other arterial thrombotic event excluded bevacizumab. Cetuximab panitumumab seem safety profile compared patients, either as single agent combination Thus, condition mCRC setting.